GMS Ventures & Investments

GMS Ventures & Investments insider trades: Outlook Therapeutics (OTLK) stock purchases

Outlook Therapeutics Last trade Aug 12, 2026 12 Form 4 filings
$0
Sold, last 12 months
0 sales
$7.5M
Bought, last 12 months
2 buys
4
Open-market trades
since 2021
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where GMS Ventures & Investments reports to the SEC

Open-market buys and sales

4 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 12, 2026OTLK↑ Buy$2.5M
May 28, 2026OTLK↑ Buy$5.0M
Nov 29, 2021OTLK↑ Buy$20.0M
Feb 2, 2021OTLK↑ Buy$8.4M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other OTLK insiders

Open-market trades in the last 12 months

About GMS Ventures & Investments's insider trades

GMS Ventures & Investments is an insider at Outlook Therapeutics (OTLK). Since Feb 2, 2021, it has reported 4 open-market purchases worth $35.9M and no sales on SEC Form 4. In the last 12 months: 2 buys ($7.5M).

Its filings also include grants and awards (6 filings), other transactions (4 filings), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OTLK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.